β-caryophyllene (BCP) exhibits anti-proliferative properties in cancer cells. Here, we examine the hypothesis that BCP induces membrane remodeling. Our data show that high concentrations of BCP increase membrane permeability of human breast cells (hBrC) causing detachment and cell death. At a sub-lethal concentration of BCP, we show that BCP induces a striking upregulation of genes involved in cholesterol biosynthesis, including the gene that encodes for HMGCoA reductase (HMGCR), the ratedetermining step in cholesterol biosynthesis. In addition, stearoyl-CoA desaturase (SCD) is also upregulated which would lead to the enhanced formation of monounsaturated fatty acids, specifically oleate and palmitoleate from stearoyl CoA and palmitoyl CoA, respectively. These fatty acids are major components of membrane phospholipids and cholesterol esters. Together, these data suggest that cells respond to BCP by increasing the synthesis of components found in membranes. These responses could be viewed as a repair mechanism and/or as a mechanism to mount resistance to the cytotoxic effect of BCP. Blocking HMGCR activity enhances the cytotoxicity of BCP, suggesting that BCP may provide an additional therapeutic tool in controlling breast cancer cell growth.
Introduction
World-wide, breast cancer is the most common form of cancer in women (1). Failure to treat metastatic disease is the leading cause of death (2) . Although substantial progress has been made towards treating cancer, such as surgical resections or adjuvant therapies, highly aggressive cancers remain a challenge. One of the deadliest types of cancers in women is triple negative breast cancer (TNBC), where expression of the estrogen, progesterone, and HER2 receptors is either low or absent (3) . This type of cancer is one of the most difficult to treat due to lack of targeted therapies and its inherent therapeutic resistance. TNBC accounts for a disproportionate number of breast cancer deaths (4) .
Notable success in the search for novel anti-cancer drugs in natural products has been achieved from the unique chemical reactions associated with plants. Plants create remarkably complex chemicals beyond those that are required for their own growth and reproduction (5) . For generations, these "specialized" metabolites have been used in the treatment of human diseases, even though their active components and molecular targets are not always well-defined (6) . While specialized metabolites are derived from a number of biosynthetic pathways, terpenes are the most abundant class of plant secondary metabolites (7) . In plants, terpenes are synthesized through the traditional mevalonate pathway (MVP) which produces the intermediates, isopentenyl pyrophosphate and dimethylallyl pyrophosphate from which terpenes derive, but also via the methylerythritol phosphate pathway (8) . The MVP produces an array of monoterpenes, diterpenes, tetraterpenes, and precursors of complex sterols (9, 10) . Some plant terpenoids are already well-established for the treatment of breast cancer. For example, paclitaxel (sold under the trade name of Taxol) is an oxygenated diterpenoid that was originally isolated from the Pacific Yew and first shown to stabilize microtubules in the Horwitz lab (11) As noted by Heinig et al., synthetic paclitaxel is arguably the most successful anticancer drug of all time (12) , and is one of the cytotoxic drugs of choice for the treatment of triple negative and drug resistant (recurrent) breast cancers (13) .
Over the last decade, a number of investigators have demonstrated that β-caryophyllene (BCP) exhibits anti-proliferative properties in cancer cells (6, (14) (15) (16) (17) (18) (19) . BCP is a bicyclic sesquiterpene ( Figure 1) and a major plant volatile of many plant essential oils (like cloves, oregano, black pepper, cinnamon, and cannabis). BCP is often found with small quantities of isocaryophyllene, the oxide form of caryophyllene, and humulene. It was the first known "dietary cannabinoid" and has achieved GRAS (Generally Recognized as Safe) status. Because of its unique taste and pleasant odor, BCP has been used in cosmetics and as a flavoring since the mid 1900's and has FDA approval. It also has well-known antipathogenic properties in plants (20) , as well as anti-inflammatory (17, 21) , anti-nociceptive (22) , and antimutagenic (23) properties in animals. Over a decade ago, Legault and Pichette demonstrated that BCP stimulates the accumulation of paclitaxel in DLD-1 (colon cancer) cells, implicating enhanced membrane permeability as a mechanism of action (19) . Indeed, BCP has been shown to interact directly with phospholipid bilayers increasing membrane fluidity (24) . Earlier studies in E.coli showed that cyclic hydrocarbons, including terpenes, interact directly with biological membranes (25) . Accumulation of these hydrocarbons results not only in increased membrane fluidity, but also in membrane swelling, both signs of cell stress. At biological temperatures, membrane fluidity is controlled by the saturation state of the acyl chains of fatty acids (primarily in phospholipids) and cholesterol content (26) . Changes in either of these parameters could lead to membrane remodeling which can affect membrane function.
Here, we examine the hypothesis that BCP induces membrane remodeling. Our data show that high concentrations of BCP increase membrane permeability of human breast cells (hBrC) causing detachment and cell death. At a "sub-lethal" concentration of BCP, we show that BCP induces a striking upregulation of genes involved in cholesterol biosynthesis, including the gene that encodes for HMGCoA reductase (HMGCR), the rate-determining step in cholesterol biosynthesis. Many of the identified genes are regulated by the transcription factor SREBP-2 whose activation is regulated by cholesterol availability (for review see (27) ). In addition, stearoyl-CoA desaturase (SCD1) is also upregulated. This endoplasmic reticulum (ER) enzyme catalyzes the rate-limiting step in the formation of monounsaturated fatty acids, specifically oleate and palmitoleate from stearoyl CoA and palmitoyl CoA, respectively. These fatty acids are major components of membrane phospholipids, cholesterol esters, and alkyldiacyglycerol. Together, these data suggest that cells respond to sub lethal concentrations of BCP by increasing the synthesis of components found in membranes. These responses could be viewed both as a repair mechanism and potentially as a mechanism to mount resistance to the cytotoxic effect of BCP. We hypothesize that blocking the repair mechanism would enhance the cytotoxicity of BCP. This might provide an addition therapeutic tool in controlling breast cancer cell growth assuming that specificity could be established. supplemented with 5% horse serum (Sigma Aldrich), 10 µg/ml insulin (Eli Lilly), 20 ng/mL epidermal growth factor (EGF) (Upstate Biochem) and 100 ng/mL dexamethasone (Sigma Aldrich). The T47D cells were maintained in McCoy's medium (Gibco) containing 10% fetal bovine serum (FBS; Sigma Aldrich) and 1µg/mL bovine insulin (Elanco). The MDA-MB-231-LM2 and UFH-001 cell lines were cultivated in DMEM supplemented with 10% FBS.
Materials and Methods

Cell
Viability assays:
To measure the viability of cells exposed to β-caryophyllene (Sigma/Aldrich # 22075), we measured mitochondrial function using thiazolyl blue (MTT) from Sigma/Aldrich (# M5655). Briefly, cells were seeded in 96 well plates and treated with increasing concentration of drugs. The cells were incubated with BCP for 4h, 8 h, and 24 h under normoxic conditions. In some experiments, we tested the effect of paclitaxel for a duration of 24 h or 48 h. Thiazolyl blue was added 4 h before the end of each time point. The medium was then removed without disrupting the cells and DMSO was added for 15 min to each well. Absorbance was read at 570 nm using an Epoch microplate reader (Biotek). Data represent the average ± SEM of three biological replicates.
Cytotoxicity assays:
To measure the cytotoxic effects of BCP and paclitaxel, we used the release of lactate dehydrogenase (LDH), measured as the production of NAD (Sigma/Aldrich, # MA0K066). Cells were grown in 35 mm dishes and exposed to specific concentrations of BCP at times indicated in the figure legends. In some experiments, we tested the effect of paclitaxel over 48 h. At high concentrations of BCP, but not of paclitaxel, it was noted that cells were released from the plate. Medium was separated from cells by centrifugation (13, Membrane preparation: Cells were washed 3 times with ice cold PBS. Cells were then homogenized in buffer containing 20 mM Tris base, 1 mM EDTA, and 255 mM sucrose, pH 7.4, supplemented with 1 mM phenylmethyl sulfonyl fluoride (PMSF) and protease inhibitor cocktail (Sigma/Aldrich, P-8340).
Membranes were collected by centrifugation at 212,000 x g for 60 min at 4°C. Membranes were resuspended in a small volume of the same buffer and stored at -20°C.
Lysate preparation: Cells were washed 3 times with ice cold PBS and then extracted in RIPA buffer [1% Triton X-100, 10 mM Tris-HCl (pH 8.0), 140 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% sodium deoxycholate, 0.1% SDS] supplemented with PMSF and protease inhibitor cocktail for 15 min on ice.
Lysates were clarified by centrifugation at 212,000 x g for 60 min at 4°C. Clarified supernatants were collected and stored at -20°C. Protein concentrations for both membranes and cell lysates was determined using the Markwell modification of the Lowry procedure (30) .
SDS-PAGE and Western blotting:
One-dimensional SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed essentially as described by Laemmli et al. (31) . Protein samples were mixed with sample dilution buffer. Gels (10%) were typically run overnight at room temperature at approximately 45 V in a Hoefer SE 600 electrophoresis unit. Protein samples were electro-transferred from SDS-PAGE gels to nitrocellulose membranes in transfer buffer (25 mM Tris-base, 192 mM glycine, 20% methanol) at 200 mA for 2 h at 4°C. Western blotting was accomplished as previously described (32) . Enhanced chemiluminescence (ECL) was used according to manufacturer's directions (GE Healthcare, #RPN2106 or RPN2232). Santa Cruz antibodies were used for analysis of HMGCR (sc-271595) and Na + K + ATPase (sc-28800). The GAPDH antibody was from Cell Signaling (D16H11). Band intensity was quantified using Un-Scan-It (Silk Scientific, Inc.) in the linear range of the film.
Cholesterol Quantification: Cholesterol concentration was estimated using a kit from Sigma/Aldrich 
Results
Effect of BCP on metabolic function and cytotoxicity in breast cancer cells
Because it has been reported that BCP enhances growth inhibition in a prostate cell line induced by paclitaxel (19) This was not surprising given that these cells replicate more quickly, in our hands, than the MCF10A or T47D cells. However, we were unable to detect any amplification by 70 µM BCP on paclitaxel induced cell growth (Supplementary Figure 1C) . The BCP concentration used here was similar to that used by Legault and Picchet (19) . While paclitaxel induced some cytotoxicity in the UFH-001 line as measured by lactate dehydrogenase (LDH) release from cells, BCP at 70 M did not further influence cytotoxicity of either the UFH cells or the other cells tested (Supplementary Figure 1D) . Reasons for these differences between our data and those previously published could be related to the sensitivity of the breast cancer cell lines relative to the prostate line used previously. That said, we must still conclude from our data that paclitaxel action in the cell lines that we tested is not potentiated by BCP.
Earlier studies reported that BCP exhibits anti-cancer activity but that the EC 50 values vary with cell type (15) . We repeated these experiments to determine if BCP is cytotoxic to the four hBrC lines and to establish dose-response curves. We again measured LDH release, this time over 4 h, in the presence or absence of specific concentrations of BCP concentrations. In Figure 1 , we show the total LDH activity released during that time frame (Panel A), the activity with the background subtracted (Panel B), and normalized data in percent released (Panel C). In agreement with earlier studies, the sensitivity to BCP Figure 1C) occurs at 200 M while cytotoxicity requires higher concentrations ( Figure   1C ). This opened an opportunity to investigate mechanisms that might be responsible for BCP action in the absence of cytotoxicity.
Effect of BCP on transcriptional activity in UFH-001 cells
The UFH-001 line exhibits the TNBC phenotype, are fast growing in culture, and form tumors in mouse models (28) . Even though these were not the most sensitive to BCP, we chose to analyze UFH001cells because targeted therapies for TNBC patients are not available. Because hypoxia is the environment associated with aggressive breast cancers, and an independent prognosticator for poor patient outcome (34), we also chose the condition of hypoxia to evaluate the effect of BCP. In addition, RNA was isolated from cells to determine changes in the transcriptome of cells exposed to BCP.
As a first approach, we selected differentially expressed genes based on FDR adjusted p-values (q-values) of <0.05, and analyzed this gene set for pathway involvement using the Reactome database. Because
Reactome also assesses the FDR for pathway analysis, we again selected an FDR <0.05 to enhance specificity. Data complied in Table 1 show that lipid metabolism in pathways regulated by the SREBP family of transcription factors are key targets of BCP action. Also of note in Table 1 is the activation of inflammatory processes through interleukin 10 (IL10) signaling and processing of interleukin 1 (IL1)
suggesting that the cells are experiencing ROS-mediated stress.
The exceptional specificity of BCP action is illustrated in Figure 3 These are major components of membrane phospholipids, and suggest that BCP-treated cells may respond to membrane damage by enhancing the biosynthetic path for both fatty acids and cholesterol.
BCP increases HMGCR expression and cholesterol content
Western blot analysis was used to assess the expression of the HMGCR. BCP had no affect on 
Simvastatin increases BCP-induced cytotoxicity
The action of BCP appears to be concentration dependent. At sub-cytotoxic levels is appears to promote lipid biosynthesis which may be used to membrane biosynthesis while a very high concentrations it induces cytotoxicity (cell death). We hypothesized that blocking cholesterol biosynthesis at sub-lethal concentrations of BCP would enhance cytotoxicity. To test this, we first analyzed the effect of two inhibitors (Atorvastatin and Simvastatin) of HMGCR on cell growth of UFH-001, T47D, and MCF10A cells using in the MTT assay (Figures 7 A-C) . The sensitivity of these drugs varied with cell type: UFH-001 > T47D > MCF10A based on IC 50 values. In each cell line, Simvastatin was a better inhibitor of cell growth than Atorvastatin under our conditions. Simvastatin also sensitized UFH-001 cells to the cytotoxic effects of BCP (Figure 7 ), but this shift was only about 2-fold.
BCP activates a feed back loop
Besides the genes that encode for the enzymatic reactions in cholesterol and lipid biosynthesis, we also evaluated the transcription of key regulators of cholesterol homeostasis ( Figure 5 ). SREBP-1 transcripts were elevated relative to SREBP-2, which is the more selective over cholesterol biosynthesis.
Although it would appear that transcription of SREBP-1 and SREBP-2 are regulated in opposite directions by BCP, neither of these changes achieved a q value of ≤ 0.05. When cholesterol levels are low, both SREBP-1 and SREBP-2 are escorted to the Golgi by the cholesterol sensing protein, SREBP cleavage-activating protein (SCAP). SCAP transcription is not affected by BCP. In the Golgi, the SREBPs encounter two specific proteases, S1P and S2P. These are responsible for the sequential cleavage of the SREBP's to generate the "mature" transcription factor that then travels to the nucleus.
Transcription of neither S1P nor S2P were enhanced by BCP. GP78 and TRC8 are E3 ubiquitin ligases leads to the re-organization of these domains followed by activation of specific signaling pathways (43) .
In cancer cells, changes in PM lipid composition, among other events, allows the recruitment of selective heat shock proteins like GRP78 (glucose-regulated protein 78) by the GRP78 co-factor, HJT-1 (44).
GRP78 is normally a resident of the ER where it regulates protein processing and the unfolded protein response (45) . Localization GRP78 to the PM of cancer cells exhibit therapeutic resistance (46) . While transcription of GRP 78 (HSPA5) is not affected by BCP, we have not measured its translocation to the PM. However, we might expect this if alterations in PM lipid concentration, induced by BCP, serves to recruit GRP78 initiating the resistance response.
Is cholesterol content or redistribution within the PM the key to understanding BCP action?
Cholesterol levels in membranes are tightly regulated. Ninety percent of the free cholesterol in cells is associated with the plasma membrane (PM), while smaller pools are found in intracellular membranes like endosomes, secretory vesicles, and caveolae (47, 48) . The ER, where the SREBPs and cholesterol sensing proteins reside, contains only about 1% of the cell's cholesterol (47, 49 Another possibility is to change the structure of BCP to make it a better cytotoxic reagent. Terpenes are not the best starting material for drug development. However, studies from the Gertsch lab (64) showed that removing the conformational constraints induced by the medium-sized ring and by introducing functional groups at the sesquiterpene hydrocarbon 1 (see Figure 1 for carbon labeling), this new scaffold created a structure that not only binds to the CB 2 receptor, but reversibly inhibits fatty acid amide hydrolase, the major endocannabinoid degrading enzyme. This might serve to prolong the effects of BCP, and make possible its use at lower concentrations.
In conclusion, we have shown that BCP induces a striking transcriptional upregulation of the cholesterol biosynthetic pathway, possibly providing cytoprotection for membrane structures and/or inducing drug resistance. However, blocking this path increases BCP-induced induced cytotoxicity suggesting a strategy for combinatorial therapy. In future studies, we will examine changes in membrane lipid and protein composition, the association with GRP78 translocation, and metabolic flux in lipid biosynthetic pathways in BCP-treated cells. RNA was isolated from UFH-001 cells exposed to hypoxia in the absence or presence of BCP. RNAseq was performed at the University of Louisville (see Table 1 ). Red asterisks next to each gene represent a significant induction (q = 0.05) for that gene. Up-regulated genes include those in both the cholesterol and lipid biosynthesis pathways. The central figure was modeled after that in Horton et al. (35) . 
